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ABSTRACT
Introduction: Cradle cap is a very common
condition in infants that presents as greasy,
scaly patches on the scalp within the first weeks
of life. Although usually disappearing by itself,
the condition worries parents because of its
appearance. When removing the scales, it is
crucial to prevent spot bleedings to avoid
infections. The investigational medical device
LOYON (Cetiol CC, dimethicone) solution
(G. Pohl-Boskamp GmbH & Co. KG,
Hohenlockstedt, Germany) has the potential
to meet these needs since it removes scales
gently. It was, therefore, the aim of this proof-
of-concept study to assess the efficacy and safety
of topically applied, non-medicated LOYON in
facilitating the removal of scaling in infants and
children with cradle cap without inducing spot
bleedings.
Methods: This single-center, open, proof-of-
concept, pilot study was conducted in 20 male
or female infants/children aged 3–36 months
with clinically diagnosed cradle cap. The 8-day
study period included one to three applications
of LOYON. Clinical assessment of scaling and
secondary parameters was performed at baseline
and after treatment. Adverse events were
recorded. A questionnaire on subjective
efficacy and usability was handed out to the
parents.
Results: With a maximum of three applications
of LOYON applied to 20 subjects, a reduction
in scaling intensity from moderate or severe to
very mild or mild was achieved in 80% of the
subjects. Treatment success, defined as the
reduction of the scaling baseline score by at
least two points, was achieved in 50% of
subjects. Results of this study do not indicate
any safety concern. No spot bleedings were
observed. LOYON was generally well tolerated
and overall treatment was rated as ‘‘good’’ by
the parents/legal guardians.
Conclusion: This study suggests that LOYON
is well tolerated, safe and effective in facilitating
the removal of scaling in infants and children
with cradle cap. With its gentle approach and
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rapid effect, LOYON thus represents a good
alternative to home remedies for treatment of
cradle cap.
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INTRODUCTION
Cradle cap is a form of seborrheic dermatitis
that mainly manifests as thick, crusty, yellow
scales on the scalp of infants and young
children. It is a very common condition,
usually appearing within the first 6 weeks of
life and clearing spontaneously by about
6–9 months of age [1, 2]. The prevalence of
cradle cap is rarely reported. According to Foley
et al. [3], the overall age- and sex-adjusted
prevalence of seborrheic dermatitis in
Australian preschool-aged children was 10%. A
prevalence of 9.6 per 1,000 persons aged
1–5 years was reported in one study from the
United States [4]. An incidence of 10% was
observed for newborns in one investigation of
neonatal cutaneous lesions from India [5].
Many factors including proliferation of the
yeast Malassezia furfur (formerly Pityrosporum
ovale), transplacental hormones and
dysfunction of the sebaceous glands have been
implicated in the pathogenesis of cradle cap,
however, its exact etiology and pathogenesis are
still unknown [2, 6, 7].
The distinction between cradle cap or
infantile seborrheic dermatitis and other skin
disorders such as atopic dermatitis and psoriasis
can be difficult in infants. This is due to the
considerable overlap of clinical features such as
hyperkeratosis, inflammation, pruritus and hair
loss and combined forms which may exist [8, 9].
Distinguishing features may involve age at onset,
course, distribution and pruritus. Whereas cradle
cap is characterized by its early onset, mild and
self-limited course, typical clinical picture,
absence of itch and discomfort, atopic
dermatitis is a chronic pruritic disease that may
present as early as 3 months of age and due to
severe itching and irritation can be extremely
bothersome to the child. Psoriasis, on the other
hand, is uncommon in this age group and is
characterized by sharply demarcated
erythematous lesions surmounted by a silvery
scale [1, 2, 7, 10].
Although cradle cap usually resolves within
6–8 weeks [11], some cases may persist longer,
and even if lasting for only a few weeks the
condition worries parents because of its
appearance [1]. Cradle cap may also have a
bad smell. That is why caregivers generally want
to act rather than wait for the condition to
spontaneously resolve, even if medical
treatment is usually not indicated. Although
the majority of cases would require little, if any,
treatment, medical intervention may be
indicated in some cases. For example, if
moisture accumulating under the scales causes
pruritus and leads the infant to scratch affected
areas, resulting skin lesions may provoke
secondary infections necessitating medical
treatment. Where medical therapy is
indicated, thick layers of scales might prevent
medications from reaching their target sites.
When removing the scales in cradle cap or other
cutaneous disorders that share a similar clinical
picture such as psoriasis, it is crucial to use a
gentle approach to prevent spot bleedings to
avoid the occurrence of infections.
Management of cradle cap depends on the
severity of the disease. In mild cases, daily
shampooing using a non-medicated baby
shampoo may be effective in loosening and
removing scales. Should simple shampooing
prove ineffective, emollients such as warmed
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mineral or olive oil or white petrolatum are often
applied to soften scales, followed by gentle
removal with a soft hairbrush and shampooing.
In severe or persistent cases, emollients in
combination with medical treatments may be
used, with reported topical medications
including keratolytic agents like salicylic acid,
anti-inflammatory agents such as low-potency
steroids, antimycotics, for instance
ketoconazole, and antibiotics [1, 12–14]. Gentle
approaches will suffice to treat most infants with
cradle cap, with non-medicated topicals serving
as first-line treatment to facilitate removal of
scales and reduce the need for medical
treatments carrying potential risks, which is of
particular importance in this age group.
Although generally not indicated, medications
may be required in a few cases as second-line
treatment; however, their use in infants and
young children is highly debatable, due to
unproven efficacy and a general lack of rigorous
safety data in this age group. Safety concerns of
conventional medical treatments include
salicylism resulting from percutaneous
absorption of salicylic acid and local or
systemic effects produced by percutaneous
absorption of steroids, e.g., skin atrophy or
adrenocortical suppression. With regard to
antimycotics or antibiotics, these should only
be used in established mycoses or bacterial
infections, respectively, otherwise the benefits
are questionable [1, 7, 10, 15–17].
Limited evidence exists regarding the
benefits of currently available treatment
modalities for cradle cap [15]. Especially non-
medicated symptomatic measures, for example
home remedies such as olive oil, are not well
investigated and controversially discussed [18–
20]. Natural oils further have the disadvantage
of lacking standardization, and some of them
cannot be used in case of allergy, for example,
arachis oil should not be used in a child who is
allergic to peanuts [1]. Hence, products with
proven clinical safety and efficacy are still
needed for cradle cap; these should preferably
not pose a pharmacological burden in this
patient population and should not result in
spot bleedings. Therefore, a new topical, non-
medicated product for facilitating the removal
of scaling in infants and children with cradle
cap has been developed, the investigational
medical device LOYON (Cetiol CC,
dimethicone) solution (G. Pohl-Boskamp
GmbH & Co. KG, Hohenlockstedt, Germany).
LOYON, which is referred to as
investigational medical device (IMD) during
the present study, is a solution containing
Cetiol CC (dicaprylyl carbonate) (BASF SE,
Ludwigshafen, Germany), a fast spreading
emollient with excellent dermatological
compatibility [21], and two dimethicones
(polydimethylsiloxane/silicones), which serve
as skin protectants and moisturizers [22].
These components have a long history of safe
use. They are found in medicinal products,
medical devices and cosmetics. Its viscosity and
creeping/spreading properties allow the IMD to
readily flow underneath the scales and remove
them in a gentle way. Softening of the scales by
the solution further eases their removal. Due to
the gentle physical removal process, spot
bleedings are likely avoided. In addition, given
its mode of action, the effectiveness of the IMD
is independent of the cause which leads to the
skin alterations: the IMD thus appears capable
of removing scales present in several clinical
entities such as cradle cap, seborrheic dermatitis
and psoriasis.
The aim of this proof-of-concept study was
to evaluate the efficacy and safety of topically
applied, non-medicated LOYON in facilitating
the removal of scaling in infants and children
with cradle cap of the scalp without inducing
spot bleedings.
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METHODS
This single-center, open, proof-of-concept, pilot
study was conducted from November 1, 2011 to
February 21, 2012 at Bioskin GmbH, Berlin,
Germany.
Compliance with Ethics Guidelines
All procedures were followed in compliance
with Good Clinical Practice (GCP) and in
accordance with the Declaration of Helsinki of
1975, as revised in 2000 and 2008, and national
laws and regulations. Informed consent was
obtained for all parents/legal guardians
included in this study. The investigational
medical device (IMD), LOYON (Cetiol CC,
dimethicone) solution, was manufactured by G.
Pohl-Boskamp GmbH & Co. KG,
Hohenlockstedt, Germany (Note: during
process of study the official brand name
changed from Loion to LOYON).
Male or female infants/children aged
3–36 months with clinically diagnosed cradle
cap on the scalp and a scaling score of at least 2
on a 5-point scale from 0 to 3 (0, 0.5, 1, 2 and 3)
were eligible for the study. For study inclusion,
the physical examination of the scalp had to be
without abnormal findings, unless the
investigator considered an abnormality
irrelevant to the outcome of the study.
Subjects were excluded from this study, if they
experienced symptoms of a clinically significant
illness with potential influence on the outcome
of the study within 4 weeks prior to or during
the study, if they suffered from inflammation,
tinea capitis or psoriasis capitis, if they used
dimethicone containing shampoos and/or if
they participated in another clinical trial
within 4 weeks prior to or during the study.
Further exclusion criteria were known
hypersensitivity to components of the study
preparation and treatment within 4 weeks prior
to or during the study with systemically or
locally acting drugs such as steroids,
antimycotics, salicylic acid or other
keratolytics, or skin care products such as olive
oil with potential influence on the outcome of
the study. The use of baby shampoos was
allowed within 4 weeks prior to the study.
The IMD was not to be applied together with
other hair care or hair cosmetic products. All
relevant medication that had been taken
6 weeks prior to Day 1 and any medication,
including over-the-counter remedies, that were
taken during the study were regarded as
concomitant treatment and had to be
documented. The use of vitamin D
preparations and fluorine-containing
medications was allowed. Other concomitant
medications were to be kept to a minimum
during the study; however, if considered
necessary for the subject’s welfare and unlikely
to interfere with the study objectives, these
were allowed at the discretion of the
investigator.
The primary aim of this open, short-term
study was proof-of-concept, comparing
treatment effects with baseline. Primary
efficacy parameters were scaling in the target
area of the scalp and treatment success.
Secondary efficacy parameters were the
presence of spot bleedings, redness, time to
treatment success, and the analysis of the
parent(s)/legal guardian(s) questionnaire on
subjective efficacy, usability and further
cosmetic items. Clinical assessment of scaling
and redness was performed using 5-point scales
from 0 to 3 (0, 0.5, 1, 2 and 3). Scales used for
scoring of the target area of the scalp for scaling
and redness are shown in Table 1. Scaling and
redness were assessed separately, with the
scoring performed by two trained investigators
to assure comparable grading. Treatment
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success was defined as the reduction of the
scaling baseline score by at least two points, i.e.,
a resulting grade of 0.5 or 1 at maximum when
the initial score was 2 or 3, respectively. Time to
treatment success was determined as the
difference of the visit day of the first
occurrence of treatment success minus one
(baseline visit day). In case of no treatment
success until Day 4, the outcome was assigned
as ‘‘no treatment success’’.
Safety parameters were adverse events (AEs)
and device deficiencies. Spontaneously noted
complaints were recorded with duration,
intensity and assessment of causality with the
study preparation. Relevant medical history of
the previous three months was recorded.
Laboratory parameters were not monitored
during the course of the study. Photographic
documentation of the scalp was performed
under standardized conditions (e.g., distance,
illumination).
The 8-day study schedule included a baseline
visit, depending on treatment success one to
three control visits, and a follow-up visit. On
the first day of the study, the target area,
defined as the worst affected area on the scalp,
was selected and its location on the scalp was
documented. The outline of the affected area
and the target area were traced onto a
transparent plastic sheet. Baseline scores for
scaling in the target area of the scalp and for
secondary parameters were assessed. Following
baseline evaluation, all subjects were treated at
least once (Day 1). In case of no treatment
success, i.e., a reduction of the scaling baseline
score by less than two points, further treatments
were performed on Days 2 and 3. The target area
and adjoining areas were treated, with the study
drug administration performed by the
parent(s)/legal guardian(s) under supervision
of Bioskin staff according to the instructions
for use. The IMD was pipetted drop wise to the
entire affected area of the dry scalp, excessive
solution was swabbed with a soft paper tissue
and the solution was spread by gentle massage
until the area was completely moistened. The
dose to be applied was not defined and
depended on the size of the affected area. The
study preparation had to be washed off at home
by the parent(s)/legal guardian(s) at the earliest
3 h after application and at the latest before the
next site visit on the following day using a
standardized shampoo (HiPP Baby ShampooTM,
HiPP GmbH & Co. Vertrieb KG, Pfaffenhofen,
Germany). On Day 2, subjects returned to
Bioskin for assessment of scaling and further
study parameters. As long as no treatment
success was achieved, study drug
administration to the affected area was
repeated; it was carried out at most thrice.
Clinical assessment of the target area was
performed on Day 1 (before treatment), 2
(after treatment) and 8 ± 1 (at follow-up),
and—in case of no treatment success on an
Table 1 Score used to clinically assess scaling and redness in the target area of the scalp
Score Scaling Redness
0 (none) No plaques, no ﬂakes in the target area No signs of redness
0.5 (very mild) Target area showed only a few single soft plaques Very slight redness
1 (mild) Target area showed single spots or full soft plaque, soft loosened ﬂakes Slight redness
2 (moderate) Target area showed large single spots or a full plaque; some loosened ﬂakes possible Clear redness
3 (severe) Target area showed full thick, tight plaques, no loosened ﬂakes Intensive redness
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earlier day—also on Days 3 and 4. On Day 2, 3
or 4, depending on the day of treatment
success, the parent(s)/legal guardian(s) filled
out a questionnaire on subjective efficacy,
usability and further cosmetic items of the
study preparation. On Day 8 (±1), subjects
returned for a follow-up visit where scaling
and further study parameters were scored for
assessment of persistence of treatment effect
and safety. The scalp was also documented
photographically at baseline and on all further
visits including the follow-up visit.
The statistical analyses were performed at
Bioskin using the software program SAS
(Statistical analysis system (SAS) Institute Inc.,
Cary, USA) version 9.2 or higher. All analyses
were explorative and interpreted descriptively.
The intention-to-treat (ITT) analysis was based
on the full analysis set (FAS) including all
subjects who received the study device at least
once and had at least one post-baseline
assessment. The per-protocol (PP) analysis was
based on the valid cases set (VCS) including all
subjects without any major violation to the
study plan, who received all the doses and with
available values of the primary variables at all
days. All safety analyses were based on the
safety evaluation set (SES) including all subjects
who received the study preparation at least
once.
RESULTS
A total of 20 male or female infants/children
aged 3–36 months with cradle cap on the scalp
(scaling score C2) were enrolled in this study, 19
of whom completed the trial. Data of all 20
subjects were valid for the SES and FAS.
Nineteen subjects were included in the VCS.
One subject prematurely discontinued the
investigation due to an AE (fever) on Day 2,
which was assessed as unlikely related to the
study preparation. Since this subject did not
receive the full dose, this boy was excluded from
the PP population. Demographic characteristics
of the study participants are summarized in
Table 2. With regard to previous and
concomitant therapies, 12 subjects were taking
medication for prophylaxis of cold and 2
subjects took medication for treatment of cold.
Before treatment all subjects experienced
moderate to severe scaling (moderate 80% of
subjects, severe 20% of subjects). The mean
scaling score at baseline was 2.2 ± 0.4.
Following treatment with the IMD, LOYON,
a reduction of scaling intensity was seen in the
target area of the scalp skin in most of the
subjects during the study course: with one to a
maximum of three applications of the IMD to
the total affected area of the scalp a reduction
from moderate or severe to no, very mild or
mild in scaling was seen in 80% of the subjects
Table 2 Summary of subject demographic characteristics
SES/FAS VCS
Number of subjects n = 20 n = 19
Age (months)
Mean ± SD 13.2 ± 11.5 13.2 ± 11.9
Median 9.5 8.0
Min, max 3, 35 3, 35
Gender
Male 16 (80.0%) 15 (78.9%)
Female 4 (20.0%) 4 (21.1%)
Race
White 18 (90.0%) 17 (89.5%)
Black/African American 1 (5.0%) 1 (5.3%)
Mixed: White, black 1 (5.0%) 1 (5.3%)
All subjects were between 3 and 36 months of age and had
cradle cap on the scalp
FAS full analysis set, Max maximum, Min minimum, SD
standard deviation, SES safety evaluation set, VCS valid
cases set
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(Fig. 1). Complete resolution of scaling was
noted in one subject on Day 3, in one further
subject on Day 4 and in two further subjects at
the follow-up visit (Day 8 ± 1). On Day 4, the
mean scaling score was 1.0 ± 0.9, corresponding
to a mean change from baseline of -1.2 ± 0.6.
Representative photographs showing different
degrees of scalp scaling are depicted in Fig. 2.
As shown in Fig. 3, treatment success—
defined as the reduction of the scaling baseline
score by at least two points—was achieved in
50% of subjects, predominantly after 3 days of
treatment: 5% of subjects had achieved
treatment success on Day 2, additional 10% of
subjects on Day 3 and further 35% of subjects
on Day 4, yielding a time to treatment success
of 1, 2 and 3 days in 5, 10 and 35% of subjects,
respectively. No spot bleedings were observed at
any time point during the entire study period.
No redness at the target area was noted in any
subject at baseline; after treatment with the
IMD, moderate redness was observed in two
subjects (in one subject on Days 2 and 4 and in
another subject on Day 3) and very mild to mild
redness at the target area occurred in most
subjects during the study period, with the
largest percentage (75%) occurring on Day 4
(Fig. 4). At the follow-up visit resolution of
redness was observed in 53% of the subjects.
The results recorded by the investigators are
in agreement with the positive treatment
evaluations by the parents/legal guardians.
According to the judgment by most parents/
legal guardians the product is easy to apply
(90% of parents/legal guardians), has a
comfortable consistency (80%) and brings
about a significant improvement of skin
appearance (85%). 70% of them were satisfied
with the improved skin appearance in their
children, with 20% experiencing this as
positively affecting the relationship to their
child. In one subject, an unpleasant odor of
the affected skin had been noted at baseline
which improved with treatment. Overall
treatment with the IMD was rated as ‘good’.
Regarding safety, a total of seven non-serious
AEs of mild to moderate intensity were reported
in five subjects (Table 3). Two AEs concerned
itching and were assessed as probably related to
the study preparation and the procedure. In a
Fig. 1 Clinical assessment of scaling during the study
course. The target area of the scalp was scored for scaling on
Day 1 (baseline), and after treatment on Day 2, on Days 3
and 4 in case of no treatment success on an earlier day and
on Day 8 using the scale shown in Table 1
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further child, soft yellow crusts with tiny
vesicles and no signs of infection or pruritus at
the application area were noted. This AE was
assessed as possibly related to the study
preparation, with the investigator suggesting
an accumulation of sweat under the crust. The
other four AEs (cold with fever, fever, rhinitis
and conjunctivitis) were considered as unlikely
related to the study preparation. Whereas five
AEs had resolved at the end of the study, two
AEs [cold with fever and fever (dropout on Day
2)] were still ongoing on Day 8, follow-up by
phone revealed that both affected subjects had
made a full recovery. There were no device
deficiencies recorded during the study.
DISCUSSION
As opposed to conventional treatments for
cradle cap that often contain salicylic acid,
steroids or antimycotics, the IMD (LOYON)
does not contain any pharmacologically active
Fig. 2 Examples of photographic documentation of the scalp. Typical photographs of severe scaling (a and c, before
treatment), mild scaling (b, after treatment) and no scaling (d, after treatment) of the target area are shown
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ingredient. Unlike medicinal products, it does
not achieve its effect by pharmacological or
immunological means, but by a physical mode
of action with the absence of systemic effects.
Its viscosity and creeping/spreading properties
allow the IMD to readily flow underneath the
scales and gently remove them. Moreover,
scales are softened by the solution,
additionally easing their removal. The aim of
the present study was proof-of-concept, i.e., the
evaluation of efficacy and safety of a topically
applied IMD in facilitating the removal of scales
in infants and children with cradle cap.
Indeed, treatment with the IMD reduced
scaling of the scalp skin in most of the infants or
children with cradle cap and the onset of effect
was rapid: an improvement was already
observed after one to three administrations. A
reduction from at least moderate scaling to mild
scaling or less was noted in 80% of subjects.
Concurrently, very mild to mild redness was
noted in most of the subjects during the study
period, i.e., in 75% of subjects on Day 4. The
presence of the two clinical findings,
improvement in scaling and appearance of
mild redness, favors the occurrence of mild
redness as being due to the removal of scales
rather than due to irritation. In more than half
of the subject, redness had disappeared at the
follow-up visit on Day 8 ± 1.
A treatment success, i.e., reduction in scaling
intensity by at least two points, was achieved in
half of the subjects. This treatment success
occurred after only one or two applications in
some subjects and was generally reached after
Fig. 3 Treatment success rate. Percentage of subjects with
treatment success achieved after 1 day (Day 2), 2 days (Day
3) and 3 days (Day 4) of treatment and at follow-up (Day
8 ± 1). Treatment success is deﬁned as the reduction of
the scaling baseline score by at least two points
Fig. 4 Clinical assessment of redness. The target area of the
scalp was scored for redness on Day 1 (baseline), and after
treatment on Days 2, on Days 3 and 4 in case of no
treatment success on an earlier day and on Day 8 using the
scale shown in Table 1
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three applications. Since cradle cap can be
rather tenacious, this is an especially
remarkable study result. In addition, treatment
effects persisted without further application, as
assessed at the follow-up. It might thus be
speculated that a longer treatment period with
the IMD would result in a greater overall
improvement of cradle cap and more subjects
showing treatment success. Indeed, with a
maximum of 3 days of treatment and a clinical
investigation period of 8 (±1) days, the
treatment period tested in this proof-of-
concept study was rather short when
compared to those used with other commonly
used formulations [15].
The absence of any spot bleedings supports
the assumption that the IMD acts in a
particularly gentle way. Hence, treatment with
the IMD may facilitate the removal of scales
while minimizing the risk of infections. The
positive experiences by the parents/legal
guardians regarding the efficacy and usability
of the IMD for treatment of cradle cap
corroborate the evaluation by the
investigators. Treatment with the IMD not
only removed the scales effectively, but was
also able to relieve the distress associated with
their child’s cradle cap in the caretakers.
Results of this study do not indicate any
safety concern. The number of AEs in this study
was low, with all seven AEs being classified as
non-serious. Three of these were assessed to be
in some causal association with the study
preparation. One AE was assessed as possibly
related to the study device and concerned soft
yellow crusts with tiny vesicles resembling
accumulation of sweat under the crust. The
reaction resolved within 5 days without
treatment. Itching, which occurred in two
subjects, was assessed as probably related to
the study preparation and procedure. Overall,
the IMD appears to be well tolerated in infants
and young children. Specific risks were not
observed.
There are several limitations of this study.
First, this study involved only a limited sample
size of 20 subjects. Yet, the main intention of
this study was proof-of-concept and
corresponding studies are usually small and
obtained data may not be complete. Second,
the study period was rather short and the
number of applications limited. As for safety,
specific risks were not observed with short-term
use and, considering the composition and mode
Table 3 Adverse events reported during the study and
their characteristics
Summary of adverse event characteristics
Subjects n = 20
Number of subjects reporting no AEs 15 (75.0%)
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of action of the device, are not expected to
occur with longer use.
This pilot study has been conducted to
determine whether the IMD is effective in the
removal of scaling during treatment of cradle
cap. The chosen design allowed for a detection
of possible signals for safety concerns without
exposing a huge group of participants.
The study provided first evidence for the
effectiveness of the IMD during the treatment
and pointed to a good safety profile. However,
there is a need for further trials to compare the
IMD with other options for removal of scaling,
such as olive oils or baby shampoos.
With regard to efficacy, treatment duration
with only three applications was sufficient to
achieve rapid improvement in 80% of the study
participants. Third, this study lacked a
comparator group. However, there are no
official guidelines on cradle cap and a
generally accepted reference treatment does
not exist. Since cradle cap usually lasts a few
weeks or months until it clears by itself it seems
very unlikely that cradle cap improved
spontaneously in all of the treatment
responders (15 of 20 subjects) during the three
study days. Therefore, the obtained
improvement in scaling is not considered an
incidental finding but a result of treatment.
Thus, the aim of this study has been reached,
i.e., the demonstration of the feasibility of using
the IMD as an effective and safe treatment
option in cradle cap.
In summary, topically applied, non-
medicated LOYON in the present study has
been well tolerated, safe and effective in
facilitating the removal of scaling in infants
and children with cradle cap. With its gentle
approach and rapid effect, LOYON thus
represents a good alternative to home
remedies with their unproven safety and
efficacy for symptomatic treatment of cradle
cap and helps to avoid unnecessary
pharmacologically or immunologically active
substances in infants and young children, when
disease-specific medical treatment is not
indicated. Thus, the results of this proof-of-
concept study are very promising. They need to
be confirmed, however, in larger prospective
randomized controlled studies.
CONCLUSION
This proof-of-concept study provides clinical
evidence on the safety and efficacy of the IMD,
LOYON for treatment of cradle cap. LOYON,
at good tolerability, effectively descales cradle
cap and may also help to reduce the scale load
in other clinical diseases such as seborrheic
dermatitis and psoriasis, where efficient
removal of scales is not only relevant for
cosmetic reasons but may also enable
subsequently applied medications to reach
their target sites. Further studies with LOYON
are currently undertaken in the indication of
psoriasis and show promising first results.
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